ClinicalTrials.Veeva

Menu

Pronto-7: Accuracy of Non-invasive Hemoglobin Measurement in Parturients

University of British Columbia logo

University of British Columbia

Status

Completed

Conditions

Hemoglobin Levels in Blood

Treatments

Device: Pronto-7

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT01893645
H12-00755

Details and patient eligibility

About

The measurement of blood hemoglobin (Hb) concentration is a routine procedure in pregnant women. The assessment of Hb involves several steps, including a needle stick, blood collection, blood sample analysis in the laboratory, and waiting for the results.

Pronto-7 (manufactured by Masimo, CA, USA) is a new portable device that allows a quick bedside Hb spot check. A finger clip probe, similar to the standard oxygen finger clip probe, provides hemoglobin values in less than 60 seconds.

In this prospective observational study the investigators will assess the clinical accuracy of Pronto-7 derived Hb values compared to the gold standard laboratory Hb values in obstetric patients. We will be calculating the mean difference between Pronto-7 and laboratory Hb values. We plan to recruit 55 pregnant women admitted for vaginal or cesarean delivery at BC Women's Hospital.

Full description

Serum hemoglobin (Hb) concentration is one of the most common laboratory tests measured when a pregnant woman (parturient) is admitted for a vaginal or cesarean delivery. The Hb concentration is normally measured from a venous blood sample in clinical laboratories using co-oximetry.

A new point-of-care pulse co-oximeter, the Pronto-7 (Masimo Corporation, Irvine, CA, USA), is a portable device that offers a non-invasive and quick spot-checking of Hb (SpHb). Measurement with the Pronto-7 takes about 60 seconds and does not require the transfer of blood samples to a laboratory. In addition to SpHb, the device provides a perfusion index (PI) value (a numeric estimation of the pulse strength at the measurement site), heart rate, oxygen saturation, and finger temperature. Potential advantages of the Pronto-7 include reduced staff work, decreased exposure to potential biohazards, and reduced pain and discomfort to the patient.

A similar technology is used in Radical-7 pulse co-oximeter (Masimo Corporation, Irvine, CA, USA) for non-invasive Hb measurement. Radical-7 has been evaluated in human volunteers undergoing hemodilution, in patients undergoing spine surgeries, major urological procedures, and in critically ill patients. However, the results regarding the accuracy of this technology are conflicting.

Enrollment

71 patients

Sex

Female

Ages

19 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Are 19 - 40 years old
  • Understand written and oral English
  • Are greater than 37 weeks gestational age
  • Have a singleton pregnancy

Exclusion criteria

  • Have a laboratory Hb less than 100 g/L
  • Have abnormal Hb disorders
  • Have hyperbilirubinemia
  • Have a peripheral vascular disease (e.g. Reynaud's syndrome)
  • Have long or acrylic nails

Trial design

71 participants in 1 patient group

Pregnant women
Description:
Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
Treatment:
Device: Pronto-7

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems